191 related articles for article (PubMed ID: 18597710)
1. Erythropoiesis-stimulating agents in oncology.
Glaspy JA
J Natl Compr Canc Netw; 2008 Jul; 6(6):565-75. PubMed ID: 18597710
[TBL] [Abstract][Full Text] [Related]
2. Erythropoietin in cancer patients.
Glaspy JA
Annu Rev Med; 2009; 60():181-92. PubMed ID: 18980468
[TBL] [Abstract][Full Text] [Related]
3. Erythropoiesis-stimulating agents: favorable safety profile when used as indicated.
Nowrousian MR; Dunst J; Vaupel P
Strahlenther Onkol; 2008 Mar; 184(3):121-36. PubMed ID: 18330508
[TBL] [Abstract][Full Text] [Related]
4. Update on safety of ESAs in cancer-induced anemia.
Glaspy J
J Natl Compr Canc Netw; 2012 May; 10(5):659-66. PubMed ID: 22570294
[TBL] [Abstract][Full Text] [Related]
5. Erythropoiesis-stimulating agents for anemic patients with cancer.
Sheikh S; Littlewood TJ
Expert Rev Hematol; 2010 Dec; 3(6):697-704. PubMed ID: 21091146
[TBL] [Abstract][Full Text] [Related]
6. Erythropoiesis-stimulating agents (ESAs): do they still have a role in chemotherapy-induced anemia (CIA)?
Bormanis J; Quirt I; Chang J; Kouroukis CT; MacDonald D; Melosky B; Verma S; Couture F
Crit Rev Oncol Hematol; 2013 Aug; 87(2):132-9. PubMed ID: 23357249
[TBL] [Abstract][Full Text] [Related]
7. Cancer patient survival and erythropoietin.
Glaspy JA
J Natl Compr Canc Netw; 2005 Nov; 3(6):796-804. PubMed ID: 16316615
[TBL] [Abstract][Full Text] [Related]
8. Anemia in cancer patients: significance, epidemiology, and current therapy.
Tchekmedyian NS
Oncology (Williston Park); 2002 Sep; 16(9 Suppl 10):17-24. PubMed ID: 12380951
[TBL] [Abstract][Full Text] [Related]
9. The use of erythropoiesis-stimulating agents in patients with non-myeloid hematological malignancies: a systematic review.
Shehata N; Walker I; Meyer R; Haynes AE; Imrie K;
Ann Hematol; 2008 Dec; 87(12):961-73. PubMed ID: 18629499
[TBL] [Abstract][Full Text] [Related]
10. American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer.
Rizzo JD; Brouwers M; Hurley P; Seidenfeld J; Arcasoy MO; Spivak JL; Bennett CL; Bohlius J; Evanchuk D; Goode MJ; Jakubowski AA; Regan DH; Somerfield MR; ;
J Clin Oncol; 2010 Nov; 28(33):4996-5010. PubMed ID: 20975064
[TBL] [Abstract][Full Text] [Related]
11. Continued challenges with the use of erythropoiesis-stimulating agents in patients with cancer: perspectives and issues on policy-guided health care.
Arbuckle RB; Griffith NL; Iacovelli LM; Johnson PE; Jorgenson JA; Kloth DD; Lucarelli CD; Muller RJ
Pharmacotherapy; 2008 May; 28(5 Pt 2):1S-15S. PubMed ID: 18447704
[TBL] [Abstract][Full Text] [Related]
12. Management of anemia in cancer patients.
Calabrich A; Katz A
Future Oncol; 2011 Apr; 7(4):507-17. PubMed ID: 21463140
[TBL] [Abstract][Full Text] [Related]
13. Current status of use of erythropoietic agents in cancer patients.
Glaspy J
Semin Thromb Hemost; 2014 Apr; 40(3):306-12. PubMed ID: 24676903
[TBL] [Abstract][Full Text] [Related]
14. The effectiveness and cost-effectiveness of erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating cancer treatment-induced anaemia (including review of technology appraisal no. 142): a systematic review and economic model.
Crathorne L; Huxley N; Haasova M; Snowsill T; Jones-Hughes T; Hoyle M; Briscoe S; Coelho H; Long L; Medina-Lara A; Mujica-Mota R; Napier M; Hyde C
Health Technol Assess; 2016 Feb; 20(13):1-588, v-vi. PubMed ID: 26907163
[TBL] [Abstract][Full Text] [Related]
15. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update.
Rizzo JD; Somerfield MR; Hagerty KL; Seidenfeld J; Bohlius J; Bennett CL; Cella DF; Djulbegovic B; Goode MJ; Jakubowski AA; Rarick MU; Regan DH; Lichtin AE; ;
J Clin Oncol; 2008 Jan; 26(1):132-49. PubMed ID: 17954713
[TBL] [Abstract][Full Text] [Related]
16. Recombinant human erythropoietin in cancer-related anemia. Review of clinical evidence.
Crawford J
Oncology (Williston Park); 2002 Sep; 16(9 Suppl 10):41-53. PubMed ID: 12380954
[TBL] [Abstract][Full Text] [Related]
17. Continuing reassessment of the risks of erythropoiesis-stimulating agents in patients with cancer.
Juneja V; Keegan P; Gootenberg JE; Rothmann MD; Shen YL; Lee KY; Weiss KD; Pazdur R
Clin Cancer Res; 2008 Jun; 14(11):3242-7. PubMed ID: 18519748
[TBL] [Abstract][Full Text] [Related]
18. Use of erythropoietin-stimulating agents in breast cancer patients: a risk review.
Crouch Z; DeSantis ER
Am J Health Syst Pharm; 2009 Jul; 66(13):1180-5. PubMed ID: 19535656
[TBL] [Abstract][Full Text] [Related]
19. September 2007 update on EORTC guidelines and anemia management with erythropoiesis-stimulating agents.
Aapro MS; Link H
Oncologist; 2008; 13 Suppl 3():33-6. PubMed ID: 18458123
[TBL] [Abstract][Full Text] [Related]
20. Erythropoiesis-stimulating agents in cancer patients: reflections on safety.
Wauters I; Vansteenkiste J
Expert Rev Clin Pharmacol; 2011 Jul; 4(4):467-76. PubMed ID: 22114856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
